What is the recommended dose of aztreonam for adults with normal and impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Aztreonam Dosing in Adults

For adults with normal renal function, aztreonam should be dosed at 1-2 grams IV/IM every 8 hours for moderately severe systemic infections, or 2 grams every 6-8 hours for severe or life-threatening infections, with the maximum recommended dose being 8 grams per day. 1

Standard Dosing by Infection Severity

The FDA-approved dosing regimen varies by infection type and severity 1:

  • Urinary tract infections: 500 mg to 1 g every 8-12 hours 1
  • Moderately severe systemic infections: 1-2 g every 8-12 hours 1
  • Severe systemic or life-threatening infections: 2 g every 6-8 hours 1

For Pseudomonas aeruginosa infections specifically, 2 grams every 6-8 hours is recommended at least upon initiation of therapy due to the serious nature of these infections. 1

Route of Administration

  • Intravenous route is recommended for patients requiring single doses greater than 1 gram or those with bacterial septicemia, localized parenchymal abscess, peritonitis, or other severe systemic or life-threatening infections 1
  • Intramuscular administration is acceptable for less severe infections 1, 2

Dosing in Renal Impairment

Aztreonam requires dose adjustment in renal impairment because prolonged serum levels occur with reduced creatinine clearance. 1 The correlation between aztreonam clearance and creatinine clearance is excellent (r² = 0.90), with a mean clearance/creatinine clearance ratio of 1.11 3

Dose Adjustment Algorithm 1:

  1. Creatinine clearance 10-30 mL/min/1.73 m²:

    • Give initial loading dose of 1-2 g
    • Then reduce maintenance dose to half the usual dose at the usual interval (every 6,8, or 12 hours)
  2. Creatinine clearance <10 mL/min/1.73 m² (including hemodialysis patients):

    • Give usual initial dose (500 mg, 1 g, or 2 g)
    • Maintenance dose: one-fourth of the usual initial dose at the usual interval
    • For serious/life-threatening infections: Give one-eighth of the initial dose after each hemodialysis session in addition to maintenance doses

Estimating Creatinine Clearance 1:

When only serum creatinine is available:

  • Males: CLcr = [weight (kg) × (140 - age)] / [72 × serum creatinine (mg/dL)]
  • Females: 0.85 × male calculation

The serum creatinine must represent steady-state renal function. 1

Duration of Therapy

Aztreonam should be continued for at least 48 hours after the patient becomes asymptomatic or evidence of bacterial eradication is obtained. 1, 4 Persistent infections may require several weeks of treatment 1, 4

Pharmacokinetic Considerations

  • Half-life in normal renal function: 1.5-2.1 hours 2, 5
  • Half-life in renal impairment: Can extend to 8.9 hours 3
  • Volume of distribution: Approximately 0.16 L/kg, approximating extracellular fluid volume 3
  • Primary elimination: Urinary excretion 2, 5
  • No significant accumulation occurs with multiple dosing in patients with appropriate dose adjustments 3

Special Populations

Elderly patients require particular attention to renal function, as serum creatinine may not accurately reflect renal status 1. Creatinine clearance estimates should be obtained and dosage modifications made accordingly 1. Aztreonam has been shown to be both effective and safe in elderly patients, even those with impaired renal function, with creatinine clearance remaining stable or improving during treatment 6

Critical Combination Therapy

For metallo-β-lactamase-producing carbapenem-resistant Enterobacterales (CRE), combine aztreonam 1-2 grams IV every 6-8 hours with ceftazidime-avibactam, as this combination showed significantly lower 30-day mortality (19.2% vs 44%, P=0.007) compared to other agents 7

Important Clinical Caveats

  • Do not use doses smaller than indicated 1
  • The strictly gram-negative aerobic spectrum limits aztreonam's use as a single empiric agent 2, 5
  • Concurrent therapy with other antimicrobials is recommended before causative organisms are identified in seriously ill patients at risk for gram-positive or anaerobic infections 2, 5
  • Aztreonam is not nephrotoxic and represents a good alternative to aminoglycosides, particularly in patients with renal impairment 2, 6

References

Research

The monobactams.

Mayo Clinic proceedings, 1991

Research

Pharmacokinetics of aztreonam in patients with gram-negative infections.

Antimicrobial agents and chemotherapy, 1985

Guideline

Aztreonam Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Aztreonam in the treatment of serious gram-negative infections in the elderly.

International journal of clinical pharmacology, therapy, and toxicology, 1988

Guideline

Ceftazidime-Avibactam Dosing and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.